CSL comments on ATAGI advice to prefer Pfizer over AstraZeneca

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and important efforts to manufacture this vaccine which remains critical for the protection of our most vulnerable populations.

We are proud of our unique role in Australia as the only onshore manufacturer that can produce this vaccine and remain dedicated to our ongoing contribution towards this effort.

Note: In an unexpected press conference on Thursday night, Chief Medical Officer Paul Kelly announced the Australian Technical Advisory Group on Immunisation (ATAGI) had met over the recent finding of the European Medicines Agency (EMA), and recommended the Pfizer shot be preferred for adults under 50 who have not already received their first AstraZeneca dose.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.